Title: Forerunner in novel drug
development, LegoChem Biosciences
Publication: The Korea Economic Daily
(Hankyung) / WowTV
Date: 12 Jan 2015
Summary
·
Founded in 2006,
LegoChem Biosciences is a biopharmaceutical specializing in novel drug
discovery/development based on medicinal chemistry. LegoChem’s business model
is to research and develop to early stage and then out-license to pharmas and
biotechs.
·
LegoChem aims to
leap forward to become a global pharmaceutical company with Antibody-Drug
Conjugates (ADCs) technology, which combines the unique targeting capabilities
of monoclonal antibodies with the cancer-killing ability of cytotoxic drug.
To view the full article (in Korean), click here ▶
About LegoChem Biosciences
LegoChem Biosciences, Inc. (LCB) is a research-based
biotechnology company dedicated to discovering, developing, and commercializing
innovative medicines by leveraging our chemistry expertise to make conventional
biologics targeted and more potent for the benefit of patients with diseases of
high unmet medical needs. We are advancing sustainable pipelines in therapeutic
areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC),
and protein-drug conjugate (PDC).
| 
